Deciphera Pharmaceuticals Analyst Ratings
Deciphera Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/27/2022 | 2.39% | Stifel | $11 → $18 | Maintains | Hold |
09/12/2022 | 42.21% | SVB Leerink | $21 → $25 | Maintains | Outperform |
09/12/2022 | 42.21% | HC Wainwright & Co. | $20 → $25 | Maintains | Buy |
08/29/2022 | 42.21% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
08/05/2022 | 19.45% | SVB Leerink | $15 → $21 | Maintains | Outperform |
08/05/2022 | 13.77% | HC Wainwright & Co. | $15 → $20 | Maintains | Buy |
08/05/2022 | 30.83% | JMP Securities | → $23 | Upgrades | Market Perform → Market Outperform |
02/28/2022 | -65.87% | Barclays | $11 → $6 | Downgrades | Equal-Weight → Underweight |
12/01/2021 | -14.68% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
11/08/2021 | -43.12% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
11/08/2021 | -31.74% | Canaccord Genuity | → $12 | Downgrades | Buy → Hold |
11/08/2021 | 42.21% | HC Wainwright & Co. | $70 → $25 | Maintains | Buy |
11/08/2021 | -37.43% | Barclays | $50 → $11 | Downgrades | Overweight → Equal-Weight |
11/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
11/05/2021 | -43.12% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
11/05/2021 | 264.05% | JMP Securities | $70 → $64 | Maintains | Market Outperform |
08/04/2021 | 298.18% | HC Wainwright & Co. | $75 → $70 | Maintains | Buy |
05/05/2021 | 326.62% | HC Wainwright & Co. | $80 → $75 | Maintains | Buy |
03/31/2021 | 343.69% | Credit Suisse | → $78 | Initiates Coverage On | → Outperform |
02/10/2021 | 298.18% | Barclays | $85 → $70 | Maintains | Overweight |
02/10/2021 | 298.18% | SVB Leerink | → $70 | Upgrades | Market Perform → Outperform |
12/03/2020 | 326.62% | Stifel | → $75 | Initiates Coverage On | → Buy |
11/12/2020 | 298.18% | SVB Leerink | $58 → $70 | Maintains | Market Perform |
09/14/2020 | 229.92% | SVB Leerink | $54 → $58 | Maintains | Market Perform |
08/05/2020 | 207.17% | SVB Leerink | $55 → $54 | Maintains | Market Perform |
05/18/2020 | 417.63% | SunTrust Robinson Humphrey | $82 → $91 | Maintains | Buy |
05/07/2020 | 241.3% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
05/07/2020 | 241.3% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
05/06/2020 | 178.73% | JP Morgan | $50 → $49 | Maintains | Overweight |
05/06/2020 | 355.06% | HC Wainwright & Co. | $60 → $80 | Reiterates | → Buy |
04/29/2020 | 366.44% | SunTrust Robinson Humphrey | $77 → $82 | Maintains | Buy |
04/29/2020 | 212.86% | SVB Leerink | $50 → $55 | Maintains | Market Perform |
03/04/2020 | 298.18% | Barclays | → $70 | Initiates Coverage On | → Overweight |
01/22/2020 | 377.82% | Nomura | $57 → $84 | Maintains | Buy |
01/13/2020 | 338% | SunTrust Robinson Humphrey | → $77 | Initiates Coverage On | → Buy |
11/05/2019 | 207.17% | JMP Securities | $45 → $54 | Maintains | Market Outperform |
10/29/2019 | — | SVB Leerink | Upgrades | Underperform → Market Perform | |
10/03/2019 | 241.3% | HC Wainwright & Co. | → $60 | Initiates Coverage On | → Buy |
09/30/2019 | 167.35% | Jefferies | → $47 | Initiates Coverage On | → Buy |
08/14/2019 | 212.86% | Cantor Fitzgerald | $43 → $55 | Maintains | Overweight |
08/14/2019 | 269.74% | Canaccord Genuity | $50 → $65 | Reiterates | → Buy |
07/18/2019 | 138.91% | Deutsche Bank | → $42 | Initiates Coverage On | → Buy |
03/15/2019 | 184.41% | Canaccord Genuity | $55 → $50 | Maintains | Buy |
09/25/2018 | 59.27% | Leerink Swann | → $28 | Initiates Coverage On | → Underperform |
08/29/2018 | 167.35% | Raymond James | → $47 | Initiates Coverage On | → Outperform |
08/23/2018 | 201.48% | Cantor Fitzgerald | → $53 | Initiates Coverage On | → Overweight |
08/07/2018 | 212.86% | Canaccord Genuity | → $55 | Initiates Coverage On | → Buy |
06/19/2018 | — | B. Riley Securities | Downgrades | Buy → Neutral | |
06/04/2018 | 87.71% | JP Morgan | $30 → $33 | Maintains | Overweight |
05/09/2018 | 144.6% | B. Riley Securities | $52 → $43 | Maintains | Buy |
02/16/2018 | 144.6% | B. Riley Securities | → $43 | Initiates Coverage On | → Buy |
10/23/2017 | 224.23% | Nomura Instinet | → $57 | Initiates Coverage On | → Buy |
10/23/2017 | 116.15% | JMP Securities | → $38 | Initiates Coverage On | → Market Outperform |
10/23/2017 | 70.65% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
09/27/2022 | 2.39% | Stifel | 11 美元 → 18 美元 | 维持 | 保持 |
09/12/2022 | 42.21% | SVB Leerink | 21 美元 → 25 美元 | 维持 | 跑赢大盘 |
09/12/2022 | 42.21% | HC Wainwright & Co. | 20 美元 → 25 美元 | 维持 | 购买 |
08/29/2022 | 42.21% | Cowen & Co. | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
08/05/2022 | 19.45% | SVB Leerink | 15 美元 → 21 美元 | 维持 | 跑赢大盘 |
08/05/2022 | 13.77% | HC Wainwright & Co. | 15 美元 → 20 美元 | 维持 | 购买 |
08/05/2022 | 30.83% | JMP 证券 | → 23 美元 | 升级 | 市场表现 → 市场跑赢大盘 |
02/28/2022 | -65.87% | 巴克莱 | 11 美元 → 6 美元 | 降级 | 等重 → 减重 |
12/01/2021 | -14.68% | HC Wainwright & Co. | 25 美元 → 15 美元 | 维持 | 购买 |
2021 年 8 月 11 日 | -43.12% | 信托证券 | 65 美元 → 10 美元 | 降级 | 买入 → 持有 |
2021 年 8 月 11 日 | -31.74% | Canaccord Genu | → 12 美元 | 降级 | 买入 → 持有 |
2021 年 8 月 11 日 | 42.21% | HC Wainwright & Co. | 70 美元 → 25 美元 | 维持 | 购买 |
2021 年 8 月 11 日 | -37.43% | 巴克莱 | 50 美元 → 11 美元 | 降级 | 超重 → 重量相等 |
2021 年 8 月 11 日 | — | Stifel | 降级 | 买入 → 持有 | |
11/05/2021 | -43.12% | 信托证券 | 65 美元 → 10 美元 | 降级 | 买入 → 持有 |
11/05/2021 | 264.05% | JMP 证券 | 70 美元 → 64 美元 | 维持 | 市场表现跑赢大盘 |
08/04/2021 | 298.18% | HC Wainwright & Co. | 75 美元 → 70 美元 | 维持 | 购买 |
2021 年 5 月 5 日 | 326.62% | HC Wainwright & Co. | 80 美元 → 75 美元 | 维持 | 购买 |
2021 年 3 月 31 日 | 343.69% | 瑞士信贷 | → 78 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2021 年 10 月 2 日 | 298.18% | 巴克莱 | 85 美元 → 70 美元 | 维持 | 超重 |
2021 年 10 月 2 日 | 298.18% | SVB Leerink | → 70 美元 | 升级 | 市场表现 → 跑赢大盘 |
2020 年 3 月 12 日 | 326.62% | Stifel | → 75 美元 | 启动覆盖范围开启 | → 购买 |
11/12/2020 | 298.18% | SVB Leerink | 58 美元 → 70 美元 | 维持 | 市场表现 |
2020 年 9 月 14 日 | 229.92% | SVB Leerink | 54 美元 → 58 美元 | 维持 | 市场表现 |
2020 年 5 月 8 日 | 207.17% | SVB Leerink | 55 美元 → 54 美元 | 维持 | 市场表现 |
05/18/2020 | 417.63% | SunTrust 罗宾逊·汉弗莱 | 82 美元 → 91 美元 | 维持 | 购买 |
05/07/2020 | 241.3% | 野村 | 84 美元 → 60 美元 | 降级 | 买入 → 中性 |
05/07/2020 | 241.3% | 野村 | 84 美元 → 60 美元 | 降级 | 买入 → 中性 |
2020 年 6 月 5 日 | 178.73% | 摩根大通 | 50 美元 → 49 美元 | 维持 | 超重 |
2020 年 6 月 5 日 | 355.06% | HC Wainwright & Co. | 60 美元 → 80 美元 | 重申 | → 购买 |
04/29/2020 | 366.44% | SunTrust 罗宾逊·汉弗莱 | 77 美元 → 82 美元 | 维持 | 购买 |
04/29/2020 | 212.86% | SVB Leerink | 50 美元 → 55 美元 | 维持 | 市场表现 |
03/04/2020 | 298.18% | 巴克莱 | → 70 美元 | 启动覆盖范围开启 | → 超重 |
01/22/2020 | 377.82% | 野村 | 57 美元 → 84 美元 | 维持 | 购买 |
2020 年 1 月 13 日 | 338% | SunTrust 罗宾逊·汉弗莱 | → 77 美元 | 启动覆盖范围开启 | → 购买 |
11/05/2019 | 207.17% | JMP 证券 | 45 美元 → 54 美元 | 维持 | 市场表现跑赢大盘 |
2019 年 10 月 29 日 | — | SVB Leerink | 升级 | 表现不佳 → 市场表现 | |
10/03/2019 | 241.3% | HC Wainwright & Co. | → 60 美元 | 启动覆盖范围开启 | → 购买 |
09/30/2019 | 167.35% | 杰富瑞集团 | → 47 美元 | 启动覆盖范围开启 | → 购买 |
08/14/2019 | 212.86% | 坎托·菲茨杰拉德 | 43 美元 → 55 美元 | 维持 | 超重 |
08/14/2019 | 269.74% | Canaccord Genu | 50 美元 → 65 美元 | 重申 | → 购买 |
07/18/2019 | 138.91% | 德意志银行 | → 42 美元 | 启动覆盖范围开启 | → 购买 |
03/15/2019 | 184.41% | Canaccord Genu | 55 美元 → 50 美元 | 维持 | 购买 |
2018 年 9 月 25 日 | 59.27% | Leerink Swann | → 28 美元 | 启动覆盖范围开启 | → 表现不佳 |
08/29/2018 | 167.35% | 雷蒙德·詹姆 | → 47 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2018 年 8 月 23 日 | 201.48% | 坎托·菲茨杰拉德 | → 53 美元 | 启动覆盖范围开启 | → 超重 |
08/07/2018 | 212.86% | Canaccord Genu | → 55 美元 | 启动覆盖范围开启 | → 购买 |
06/19/2018 | — | B. 莱利证券 | 降级 | 买入 → 中性 | |
2018 年 4 月 6 日 | 87.71% | 摩根大通 | 30 美元 → 33 美元 | 维持 | 超重 |
2018 年 9 月 5 日 | 144.6% | B. 莱利证券 | 52 美元 → 43 美元 | 维持 | 购买 |
02/16/2018 | 144.6% | B. 莱利证券 | → 43 美元 | 启动覆盖范围开启 | → 购买 |
10/23/2017 | 224.23% | 野村本能 | → 57 美元 | 启动覆盖范围开启 | → 购买 |
10/23/2017 | 116.15% | JMP 证券 | → 38 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
10/23/2017 | 70.65% | 摩根大通 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
Deciphera Pharmaceuticals Questions & Answers
Deciphera 制药问题与解答
The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by Stifel on September 27, 2022. The analyst firm set a price target for $18.00 expecting DCPH to rise to within 12 months (a possible 2.39% upside). 16 analyst firms have reported ratings in the last year.
Stifel于2022年9月27日公布了Deciphera Pharmicals(纳斯达克股票代码:DCPH)的最新目标股价。该分析公司将目标股价定为18.00美元,预计DCPH将在12个月内上涨至18.00美元(可能上涨2.39%)。去年有16家分析公司公布了评级。
The latest analyst rating for Deciphera Pharmaceuticals (NASDAQ: DCPH) was provided by Stifel, and Deciphera Pharmaceuticals maintained their hold rating.
Deciphera Pharmicals(纳斯达克股票代码:DCPH)的最新分析师评级由Stifel提供,Deciphera Pharmicals维持其持有评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Deciphera Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Deciphera Pharmaceuticals was filed on September 27, 2022 so you should expect the next rating to be made available sometime around September 27, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Deciphera Pharmicals的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Deciphera Pharmicals的最后一次评级是在2022年9月27日提交的,因此您应该预计下一个评级将在2023年9月27日左右公布。
While ratings are subjective and will change, the latest Deciphera Pharmaceuticals (DCPH) rating was a maintained with a price target of $11.00 to $18.00. The current price Deciphera Pharmaceuticals (DCPH) is trading at is $17.58, which is within the analyst's predicted range.
尽管评级是主观的,并将发生变化,但最新的Deciphera Pharmicals(DCPH)评级维持不变,目标股价为11.00美元至18.00美元。Deciphera Pharmicals(DCPH)目前的交易价格为17.58美元,在分析师的预测区间内。